Feature | September 09, 2014

Quadripolar Lead Trumps Bipolar Option in MORE-CRT Trial Presented at ESC

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months, according to preliminary hot line results presented at the 2014 European Society of Cardiology (ESC) Congress in Barcelona.

The MORE-CRT (More Options available with a quadripolar LV lead pRovidE in-clinic solutions to CRT challenges) trial “demonstrates the safety and efficiency of the quadripolar lead technology in providing more options to manage CRT patients,” said the study’s lead investigator Giuseppe Boriani, M.D., Ph.D., University of Bologna, Italy.

CRT is a well-proven therapy for heart failure patients, who have benefitted for years with bipolar technology. Quadripolar technology is an important new advance for CRT systems that give physicians more programming options to improve patients’ response to CRT therapy and to minimize potential complications.

The CRT device is implanted under the skin with leads going into the heart. “However, in up to 10 percent of heart failure patients LV lead placement is not successful because of anatomical challenges, phrenic nerve stimulation or poor electrical measurements,” said Boriani. “Quadripolar pacing was developed with the aim of overcoming some of these barriers, but until now it has never been tested in a large, prospective, randomized trial.”

The MORE-CRT study included 1,068 heart failure patients scheduled for CRT from 63 centers in 13 countries. Patients aged approximately 68 years were randomized in a 1:2 ratio to undergo CRT with either a bipolar lead (controls; n=348) or a quadripolar lead (n=720).

The study showed that at six months, compared to controls, patients with quadripolar leads were significantly more likely to be free from a composite endpoint of both intra- and post-operative LV lead-related complications (85.97 percent versus 76.86 percent, P=0.0001) – a relative risk reduction (RRR) of 40.8 percent.

The driver of this benefit was mainly intra-operative complications, which were reduced by more than 50 percent in the quadripolar group (5.98 percent vs 13.73 percent, P<0.0001, RRR 56.4 percent), said Boriani.

There were also fewer post-operative complications in the quadripolar group, but the difference was not statistically significant. “The quadripolar lead provides more options to effectively manage common pacing complications, as compared to systems based on bipolar leads; hence, improving the efficiency of CRT,” concluded Boriani.

For more information: www.escardio.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init